We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
SWISS LAW AND TAX
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
T3 Pharmaceuticals AG, a biotechnology company with its headquarter in Allschwil, Switzerland has been acquired by Boehringer Ingelheim, a leading family-owned, research-driven biopharmaceutical company based in Ingelheim, Germany...
LASCCO SA, a biomedical-technology company, and Abionic SA, a nanotechnology company, both based at the Biopôle of Lausanne, Switzerland, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan, China, for the use of the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China.
Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round led by Pureos Bioventures.
The shareholders of the Mimacom Flowable Group ("MFG") have sold MFG to the private equity investment house Ardian, accompanied by a reinvestment of the management. The transaction was completed on 19 April 2023. Headquartered in...
Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private founders of KeriMedical, a Geneva-based private company specializing in the development and manufacture of implants for hand and wrist surgery, to acquire an additional 18% stake for a purchase price of approximately CHF 18m.
The German life science and medtech investor SHS Gesellschaft für Beteiligungsmanagement mbH has made a EUR 10 million investment in Simulands AG, a Zurich-based manufacturer of simulation devices for medical training of cardiovascular interventions.
Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.
Eurocine Vaccines and Redbiotec have signed a research and partnership agreement for the development of vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2).
STOCKHOLM - CombiGene AB and Spark Therapeutics announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project.
ombioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, entered into a worldwide licensing agreement with Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX), a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA.
Displaying results 1 to 10 out of 40
